RxDoctor Payments Data

Kenneth Laxer, MD

Neurology · San Francisco, CANPI 1861460990

Payments from drug & device makers

$468,629in general payments, 2019–2025

Across 513 payments — averaging $913.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$354K
  • UCB SA$75K
  • UCB, Inc.$18K
  • Livanova USA, Inc.$11K
  • Aquestive Therapeutics, Inc.$4K
  • Eisai Inc.$3K
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$6,7502%
  • Speaking & faculty fees$321,32585%
  • Travel & lodging$37,72610%
  • Food & beverage$12,8453%
  • Education$2640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$468,629 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$56,167
Medicare patients
215
Services billed
362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate207$294,188
FycompaPerampanel122$168,914
BriviactBrivaracetam39$85,188
Lamictal XrLamotrigine39$61,327
VimpatLacosamide24$57,285
KeppraLevetiracetam22$52,637
Lamotrigine ErLamotrigine97$50,144
Keppra XrLevetiracetam14$23,231
Clobazam154$18,296
Lacosamide103$17,757
NayzilamMidazolam17$11,109
Levetiracetam139$8,177
Carbamazepine ErCarbamazepine17$4,976
DilantinPhenytoin Sodium Extended12$2,968
Levetiracetam ErLevetiracetam21$2,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$354,237$294,188207 claims
Eisai Inc.Fycompa$3,233$168,914122 claims
UCB, Inc.Briviact, Vimpat, Nayzilam$18,082$153,58280 claims
UCB SAKeppra$75,093$52,63722 claims
Upsher-smith Laboratories LLCTopiramate$18$30617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →